Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab-Ac225 in Refractory Multiple Myeloma
NCT02998047Phase 1Terminated
- Sponsor
- Actinium Pharmaceuticals, Inc.
- Start
- Dec 2016
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lintuzumab satetraxetan ac-225 in multiple myeloma (MM), sponsored by Actinium Pharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose at 2.5 years and Adverse Events at 2.5 years. Started Dec 2016; status: terminated.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02998047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998047.